WHO WE ARE

Every patient matters

Our pipeline contains novel therapies designed to address orphan conditions of the brain and nervous system in order to improve quality of life and patient outcomes.

We partner with these patients, their families and caregivers, and healthcare professionals to provide a comprehensive approach that goes beyond treating symptoms to ensure that patients’ experiences, perspectives, needs, and priorities are meaningfully incorporated into our work.

A History of Success

We back up our commitment with a leadership team that has extensive experience with global biotech companies and a proven track record of developing and commercializing treatments for orphan central nervous system (CNS) diseases.

The Noema Team

Luigi Costa
Luigi Costa

Chief Executive Officer

George Garibaldi MD
George Garibaldi, MD

Chief Medical Officer

Mike Gutch

Mike Gutch, Ph.D.

Chief Financial Officer

Sally Nixon
Sally Nixon

Head of Operations

Renata Lazarova, MD
Renata Lazarova, MD

VP Clinical Development, Pediatric Programs

Amine Tahiri PharmD, MBA
Amine Tahiri

VP Clinical Development, Adult Programs

Simon Roitt
Simon Roitt

VP Clinical Operations

Smiljana Milosavljevic Ristic MD, PhD
Smiljana Milosavljevic Ristic MD, PhD

VP Clinical Development, Behavioral Medicine Programs

BOARD OF DIRECTORS

Jeffrey Jonas

Jeffrey Jonas, MD 

Chairman

Darren Carroll

Darren Carroll

Antoine Papiernik

Antoine Papiernik

Arthur Franken

Arthur Franken 

Catherine Moukheibir

Catherine Moukheibir

Illise Lombardo

Ilise Lombardo, MD

SCIENTIFIC Advisors

Stephen Stahl, MD, PhD

Gerald A. Maguire, MD

Terence Coderre, PhD

Tanjala T. Gipson, MD

Ali Mostajelean, MD

Andreas Hartmann, MD

Michael Doherty, MD